

ESTIMATE OF ANNUALIZED BURDEN TABLE—Continued

Target population	Data collection form	Number of respondents	Number of responses per respondent	Average burden per response (in hours)	Total burden (in hours)
Eligible HIV-positive individuals	Clinic Survey	800	1	25/60	333
Total	829

Daniel Holcomb,

Reports Clearance Officer, Centers for Disease Control and Prevention.

[FR Doc. 2011-7886 Filed 4-1-11; 8:45 am]

BILLING CODE 4163-18-P

Dated: March 29, 2011.

Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2011-7883 Filed 4-1-11; 8:45 am]

BILLING CODE 4163-18-P

Dated: March 29, 2011.

Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2011-7882 Filed 4-1-11; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review

The meeting announced below concerns Virologic Evaluation of the Modes of Influenza Virus Transmission among Humans, Funding Opportunity Announcement (FOA), IP11-001, initial review.

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting:

Time and Date: 8 a.m.-5 p.m., May 17, 2011 (Closed).

Place: Sheraton Gateway Hotel Atlanta Airport, 1900 Sullivan Road, Atlanta, Georgia 30337, Telephone: (770) 997-1100.

Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92-463.

Matters to be Discussed: The meeting will include the initial review, discussion, and evaluation of applications received in response to "Virologic Evaluation of the Modes of Influenza Virus Transmission among Humans, FOA IP11-001."

Contact Person for More Information: Gregory Anderson, M.S., M.P.H., Scientific Review Officer, CDC, 1600 Clifton Road, NE., Mailstop E60, Atlanta, Georgia 30333, Telephone: (404) 498-2293.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review

The meeting announced below concerns Economic Studies of Vaccines and Immunization Policies, Programs, and Practices, Funding Opportunity Announcement (FOA), IP11-007, initial review.

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting:

Time and Date: 12 p.m.-2 p.m., June 14, 2011 (Closed).

Place: Teleconference.

Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92-463.

Matters to be Discussed: The meeting will include the initial review, discussion, and evaluation of applications received in response to "Economic Studies of Vaccines and Immunization Policies, Programs, and Practices, FOA IP11-007, initial review."

Contact Person for More Information: Amy Yang, PhD, Scientific Review Officer, CDC, 1600 Clifton Road, NE., Mailstop E60, Atlanta, Georgia 30333, Telephone: (404) 498-2733.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

Statement of Organization, Functions, and Delegations of Authority

Part F of the Statement of Organization, Functions, and Delegations of Authority for the Department of Health and Human Services, Centers for Medicare & Medicaid Services (CMS), (**Federal Register**, Vol. 75, No. 56, pp. 14178, dated Wednesday, March 24, 2010) is amended to reflect updates to the functions for the Center for Strategic Planning (FCK).

Part F. is described below:

- Section FC. 20. (Functions) reads as follows:

Center for Strategic Planning (FCK)

- Provide senior leadership over the strategic planning process and the development of CMS strategic goals, metrics, and plans.
- Direct the development of financial and health care trend analysis and management insight report to inform senior CMS leadership strategic decision making.
- Set priorities for CSP direction, budget, personnel, and staff development.
- Translate statistical data into information useful to agency leadership.
- Provide leadership to the development of performance dashboards and databases for key agency initiatives.
- Provide leadership in maintaining and ensuring quality of data resources needed for testing and evaluating demonstrations and innovations.
- Direct the development of enterprise business plans, process requirement for CMS post ACA

administrative, provider, and customer services process.

- Facilitate plans for IT Integration of data resources and data services.
- Coordinate policy analysis, development and execution for CMS.
- Build and maintain agency capacity to perform analysis of regional variation in the quality and cost of care.
- Conduct and manage surveys to capture information about beneficiary populations that our programs serve that is not available in the administrative data. This includes the Medicare Current Beneficiary Survey (MCBS) and the Medicare Health Outcomes Survey (HOS).
- Conduct and manage the Research Data Assistance Center (RESDAC), Research Data Distribution Center (RDDC) and Chronic Condition Warehouse (CCW) activities.
- Operationalize research-usable files for Medicare, Medicaid, and CHIP administrative data.

Dated: March 24, 2011.
Marilyn Tavenner,
Principal Deputy Administrator and Chief Operating Officer, Centers for Medicare & Medicaid Services.
 [FR Doc. 2011-7903 Filed 4-1-11; 8:45 am]
BILLING CODE 4120-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Submission for OMB Review; Comment Request

Title: Reunification Procedures for Unaccompanied Alien Children.
OMB No.: 0970-0278.
Description: Following the passage of the 2002 Homeland Security Act (Pub. L. 107-296), the Administration for Children and Families (ACF), Office of Refugee Resettlement (ORR), is charged with the care and placement of

unaccompanied alien children in Federal custody, and implementing a policy for the release of these children, when appropriate, upon the request of suitable sponsors while awaiting immigration proceedings. In order for ORR to make determinations regarding the release of these children, the potential sponsors must meet certain conditions pursuant to section 462 of the Homeland Security Act and the Flores v. Reno Settlement Agreement No. CV85 4544-RJK (C.D. Cal. 1997). The proposed information collection requests information to be utilized by ORR for determining the suitability of a sponsor/respondent for the release of a minor from ORR custody. The proposed instruments are the Sponsors Agreement to Conditions of Release, Verification of Release, Family Reunification Packet, and the Authorization for Release of Information.

Respondents: Sponsors requesting release of unaccompanied alien.

ANNUAL BURDEN ESTIMATES

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
Verification of Release (UAC)	4,595	1	0.25	1,148.75
Authorization for Release of Information (Sponsor)	4,595	1	0.25	1,148.75
Family Reunification Packet (Sponsor)	4,595	1	1	4,595
Sponsors Agreement to Conditions of Release (Sponsor)	4,595	1	0.25	1,148.75
Verification of Release (Case Worker)	4,595	1	0.25	1,148.75
Authorization for Release of Information (Case Worker)	4,595	1	0.25	
Family Reunification Packet (Case Worker)	4,595	1	1	4,595
Sponsors Agreement to conditions of Release (Case Worker)	4,595	1	0.25	1,148.75

Estimated Total Annual Burden Hours: 16,082.50.
Additional Information:
 Copies of the proposed collection may be obtained by writing to the Administration for Children and Families, Office of Administration, Office of Information Services, 370 L'Enfant Promenade, SW., Washington, DC 20447, *Attn:* ACF Reports Clearance Officer. All requests should be identified by the title of the information collection. *E-mail address:* infocollection@acf.hhs.gov.

OMB Comment:
 OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the **Federal Register**. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the following: Office of Management and Budget, Paperwork

Reduction Project, *Fax:* 202-395-7285, *E-mail:* OIRA_SUBMISSION@OMB.EOP.GOV, *Attn:* Desk Officer for the Administration for Children and Families.

Dated: March 29, 2011.
Robert Sargis,
Reports Clearance Officer.
 [FR Doc. 2011-7823 Filed 4-1-11; 8:45 am]
BILLING CODE 4184-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2010-N-0474]

Maja S. Ruetschi: Debarment Order

AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is issuing an

order under the Federal Food, Drug, and Cosmetic Act (the FD&C Act) debarring Maja S. Ruetschi, MD for 5 years from providing services in any capacity to a person that has an approved or pending drug product application. FDA bases this order on findings that Dr. Ruetschi was convicted of a misdemeanor under Federal law for conduct relating to the regulation of a drug product under the FD&C Act and that the type of conduct underlying the conviction undermines the process for the regulation of drugs. Dr. Ruetschi was given notice of the proposed debarment and an opportunity to request a hearing within the timeframe prescribed by regulation. Dr. Ruetschi failed to respond. Dr. Ruetschi's failure to respond constitutes a waiver of her right to a hearing concerning this action.

DATES: This order is effective April 4, 2011.

ADDRESSES: Submit applications for termination of debarment to the Division of Dockets Management (HFA-